Frank Bridoux, head of the nephrology service at CHU Poitiers and member of the team led by Christophe Sirac, recently published in the prestigious New England Journal of Medicine (IF 74.699), in collaboration with the Mayo Clinic (Rochester, MN, USA) a review on the physiopathological and clinical aspects of monoclonal gammopathies of renal significance (MGRS).

These pathologies, which include AL amyloidosis, are linked to direct (deposition) or indirect renal toxicity (activation of complement, autoantibody activity of monoclonal immunoglobulin). They are at the heart of the team’s research projects, in particular through the development of transgenic mice expressing pathogenic human immunoglobulin and reproducing human disease, thus making it possible to explore the pathophysiological mechanisms and develop new therapeutic strategies.

Mechanisms of monoclonal immunoglobulin nephrotoxicity

 

 

Text link : click here

Contact : Frank Bridoux

Contact : Christophe Sirac

 

 

Author affiliations:

• Divisions of Nephrology and Hypertension and of Hematology (N.L.) and the Department of Laboratory Medicine and Pathology (S.H.N.), Mayo Clinic, Rochester, MN
• Department of Nephrology and Centre d’Investigation Clinique INSERM 1402, Centre de Référence Amylose AL et Autres Maladies par Dépôt d’Immunoglobulines Monoclonales, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers,
• Centre National de la Recherche Scientifique UMR7276, Université de Limoges, Limoges